- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1123838-51-6] Glesatinibhydrochloride
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-19642A |
| Brand: | MCE |
| CAS: | 1123838-51-6 |
Overview
| MDL | MFCD30344661 |
|---|---|
| Molecular Weight | 656.17 |
| Molecular Formula | C31H28ClF2N5O3S2 |
| SMILES | O=C(NC(NC1=CC=C(OC2=C3C(C=C(C4=NC=C(CNCCOC)C=C4)S3)=NC=C2)C(F)=C1)=S)CC5=CC=C(F)C=C5.Cl |
2 Publications Citing Use of MCE
Summary
Glesatinib hydrochloride (MGCD265 hydrochloride) is an orally active, potent MET/SMO dual inhibitor. Glesatinib hydrochloride, a tyrosine kinase inhibitor, antagonizes P-glycoprotein (P-gp) mediated multidrug resistance (MDR) in non-small cell lung cancer (NSCLC) [1] [2] .
In Vitro
Glesatinib hydrochloride (MGCD265 hydrochloride; 0.01-5 μM; for 72 hours) results in a dose-dependent inhibition of cancer cell growth and shows the low IC
50
value of 0.08 μM on NSCLC H1299 cells
[1]
.
Glesatinib hydrochloride (0.01, 0.1, 0.5, 1 μM) significantly increases by several-fold the percentage of apoptotic cells in NSCLC H1299 cells
[1]
.
Glesatinib hydrochloride has the cytotoxicity to P-gp overexpressing cancer cells KB-C2, SW620/Ad300, HEK293/ABCB1, and their parent cells KB-3-1, SW620, HEK293 cells with the IC
50
s fell between 5 and 10 μM
[1]
.
Glesatinib hydrochloride (1, 3 μM; 120 mins) increases the intracellular [
3
H]-Paclitaxel accumulation and inhibits [
3
H]-Paclitaxel efflux in cancer cell lines overexpressing P-gp
[2]
.
Glesatinib hydrochloride (0-40 μM) stimulates the ATPase activity of P-gp transporters in a dose-dependent manner
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Cell Proliferation Assay [1]
| Cell Line: | NSCLC H1299 cells |
| Concentration: | 0.01, 0.1, 1, 2, 5 μM |
| Incubation Time: | For 72 hours |
| Result: | Resulted in a dose-dependent inhibition of cancer cell growth and showed the lowest IC 50 value of 0.08 μM. |
In Vivo
Glesatinib hydrochloride (MGCD265 hydrochloride; 15 mg/kg/day; orally; 40 weeks) causes a significant decrease in tumor size
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | 4−6-week old female balb/c athymic (nu/nu) mice with HCC827 NSCLC tumor xenografts [1] |
| Dosage: | 15 mg/kg |
| Administration: | Orally; daily; 40 weeks |
| Result: | Caused a significant decrease in tumor size. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02954991 | Mirati Therapeutics Inc. |
Carcinoma, Non-Small-Cell Lung
|
November 7, 2016 | Phase 2 |
| NCT00697632 | Mirati Therapeutics Inc. |
Advanced Cancer
|
June 2008 | Phase 1 |
| NCT00679133 | Mirati Therapeutics Inc. |
Advanced Malignancies
|
April 2008 | Phase 1 |
| NCT02544633 | Mirati Therapeutics Inc. |
Non-Small Cell Lung Cancer
|
October 2015 | Phase 2 |
| NCT01930006 | Mirati Therapeutics Inc. |
Advanced Malignancies
|
August 2013 | Phase 1 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Solvent & Solubility
DMSO : 50 mg/mL ( 76.20 mM ; Need ultrasonic)
H 2 O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C) (insoluble)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 1.5240 mL | 7.6200 mL | 15.2400 mL |
| 5 mM | 0.3048 mL | 1.5240 mL | 3.0480 mL |
| 10 mM | 0.1524 mL | 0.7620 mL | 1.5240 mL |
References
- [1] Morgillo F, et al. Dual MET and SMO Negative Modulators Overcome Resistance to EGFR Inhibitors in Human Nonsmall Cell Lung Cancer. J Med Chem. 2017 Sep 14;60(17):7447-7458.
- [2] Cui Q, et al. Glesatinib, a c-MET/SMO Dual Inhibitor, Antagonizes P-glycoprotein Mediated MultidrugResistance in Cancer Cells. Front Oncol. 2019 Apr 25;9:313.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.